Rxo (RXO) Gross Profit (2021 - 2026)

Rxo (RXO) has 6 years of Gross Profit data on file, last reported at $254.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit fell 9.29% year-over-year to $254.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (up 5.14% YoY), and the FY2025 full-year result was $1.1 billion, up 14.82% from the prior year.
• Gross Profit for Q1 2026 stood at $254.0 million, down from $266.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $322.0 million in Q2 2022 and bottomed at $214.0 million in Q1 2024.
• The 5-year median for Gross Profit is $266.0 million (2025), against an average of $264.8 million.
• The widest annual swing landed in 2023, when Gross Profit dropped 25.47%; it then surged 31.91% in 2024.
• A 5-year view of Gross Profit shows it stood at $278.0 million in 2022, then dropped by 15.47% to $235.0 million in 2023, then jumped by 31.91% to $310.0 million in 2024, then slipped by 14.19% to $266.0 million in 2025, then declined by 4.51% to $254.0 million in 2026.
• The last three Gross Profit figures came in at $254.0 million (Q1 2026), $266.0 million (Q4 2025), and $284.0 million (Q3 2025), per Business Quant data.

Peer Comparison